Jinarc? tablets(containing tolvaptan)are now availableon the High TechMedicines Schemeand are indicated toslow the progression ofkidney disease in patientswith autosomal dominantpolycystic kidney disease(ADPKD). This is an inheritedcondition in which numerousfluid-filled cysts develop inthe kidneys, which eventuallyaffect kidney function andcan cause the kidneys tofail. Jinarc is suitable for usein patients with normal tomoderately reduced kidneyfunction at the beginning oftreatment and whose diseaseis progressing rapidly.
展开▼
